BACKGROUND The incidence of rare cutaneous malignancies is unknown. Current estimates of rare cutaneous malignancy incidences are based on broad epidemiologic data or single institution experiences, not population-based data.
R
are cutaneous malignancies are broadly categorized as nonmelanoma skin cancer (NMSC) and exclude basal cell carcinoma and cutaneous squamous cell carcinoma, the commonest forms of skin cancer. Among these tumors are atypical fibroxanthoma (AFX), eccrine carcinoma and porocarcinoma (EC and EPC, respectively), microcystic adnexal carcinoma (MAC), leiomyosarcoma (LMS), dermatofibrosarcoma protuberans (DFSP), Merkel cell carcinoma, and sebaceous carcinoma (SC). Due to the rarity of the tumors and the absence of uniform reporting for all of these malignancies, the true incidence is unknown. The purpose of the present study was to calculate the incidence and tabulate clinical characteristics of these rare NMSC from a population-based cohort.
Methods

Study Setting
This study took place in Olmsted County (OC), Minnesota. While the average socioeconomic status, proportion of college graduates, and proportion of non-Hispanic whites are higher than the national average, epidemiologic studies in OC have historically been consistent with available national data. 1 As of the 2010 US Census, the OC population was 84.0% white, 6.0% Asian, 5.5% black, 4.7% Hispanic, 0.3% Native American, 1.8% other race, and 2.4% two or more races. 2 This study was approved by the Mayo Clinic and Olmsted Medical Center institutional review boards. Incident cases were identified through the Rochester Epidemiology Project (REP), a research infrastructure (R01 AG034676) that captures health care information for virtually all residents of OC since 1966. 3 
Study Criteria
Using the REP, all medical records for OC residents who received an International Classification of Disease, Ninth Revision, diagnosis of 173.00 to 173.99 from January 2, 2000 to December 31, 2010 were identified. This code range identifies "unspecified," and "other specified" malignant neoplasms of the skin. The medical records of patients who had not denied access to their medical records for research purposes were reviewed for a histopathologic diagnosis of NMSC. Exclusion criteria included the following: (1) <18 years of age; (2) no NMSC; (3) previous diagnosis of the incident tumor prior to January 2, 2000; (4) anogenital location; and (5) not an OC resident at the time of incident tumor diagnosis. An NMSC was considered incident if it was a patient's first tumor of that type and was diagnosed during January 2, 2000 to December 31, 2010 while the patient was a resident of OC.
Data Collection
Medical records were reviewed by an abstractor (A.R.S. and J.G.M.). The following data were collected: age at diagnosis, gender, race, previous diagnosis of melanoma, smoking history, and current immunosuppression. ). There were a total of 3 recurrences and no metastases. Table 2 illustrates the overall annual age-adjusted and sexadjusted incidence for these tumors. Atypical fibroxanthoma had the highest incidence with 1.8 cases per 100,000 persons. Other NMSC within the inclusion criteria encountered in this population are listed in Table 3 . 
Male gender, n (%) 16 (84) 5 (62) 3 (60) 2 (25) 1 (25) 1 (50) (88) 4 (80) 8 (100) 3 (75) 2 ( AFX, atypical fibroxanthoma; DFSP, dermatofibrosarcoma protuberans; EC, eccrine carcinoma; ED&C, Electrodessication and Curettage; EPC, eccrine porocarcinoma; IQR, interquartile range; LMS, leiomyosarcoma; MAC, microcystic adnexal carcinoma; MMS, Mohs micrographic surgery; NMSC, nonmelanoma skin cancer; SC, sebaceous carcinoma; SD, standard deviation.
Atypical fibroxanthoma is a fibrohistiocytic tumor with an intermediate malignant potential with metastases and death infrequently reported. [4] [5] [6] [7] [8] [9] [10] Other terms for AFX have been pseudocarcinoma, fibrosarcoma, paradoxical fibrosarcoma, pseudosarcomatous dermatofibroma, pseudosarcomatous xanthofibroma, and pseudosarcomatous reticulohistiocytoma. 11, 12 The AFX has also been considered as a superficial, more benign variant of undifferentiated pleomorphic sarcoma, formerly known as pleomorphic malignant fibrous histiocytoma. 12 To the authors' knowledge, the incidence of AFX has not been reported. In a 10-year study period in New Zealand, of 50,411 NMSC AFX constituted 0.002%. 13 The study shows an AFX incidence of 1.8 per 100,000 persons with a higher incidence in men compared with women (4.0-0.4 per 100,000 respectively).
Risk factors associated with AFX are male sex, older age, ultraviolet radiation exposure, x-ray radiation exposure, xeroderma pigmentosa, and a history of transplantation. 12 Depending on the modality of treatment, the recurrence rates range from 0% to 16% 11,12,14-17 but likely 7% to 9%. 12 Metastatic rate ranges from 0.5% to 4%. 12 A recent Canadian study demonstrated a local recurrence and distant metastasis up to 14% and 4%, respectively. 18 Both excision and MMS are used to treat AFX, with recurrence rates of 8.7% and 0% to 6.9%, respectively. [15] [16] [17] 19 All AFX in the cohort were on the head and neck with men being more commonly affected (84.2%), supporting the previously reported predilection of AFX for the head/neck of men. Fifteen of our patients (88%) were treated by MMS with a recurrence rate of 5% and without metastases.
Sebaceous Carcinoma
Sebaceous carcinoma is a neoplasm derived from sebaceous glands. 20 These tumors occur most commonly on the eyelid, [21] [22] [23] comprising 0.2% to 5.5% of all periorbital malignancies and an estimated 0.05% of all cutaneous malignancies in the United States. [24] [25] [26] [27] Sebaceous carcinoma is thought to behave aggressively, and has a propensity for recurrence and metastasis. AFX, atypical fibroxanthoma; CI, confidence interval; DFSP, dermatofibrosarcoma protuberans; EC, eccrine carcinoma; EPC, eccrine porocarcinoma; LMS, leiomyosarcoma; MAC, microcystic adnexal carcinoma; NMSC, nonmelanoma skin cancer; SC, sebaceous carcinoma. NMSC, nonmelanoma skin cancer. revealed a lack of gender association, with perhaps even a slight male predominance. 22, 29 Similarly, the authors noted a majority of male patients (62%). Sebaceous carcinoma is found primarily in the elderly people 22, 23, 29 ; the cohort's mean age at diagnosis was 80.1. There is an established relationship between Muir-Torre syndrome and SC, 22, 29, 33 and several studies have shown an association with immunosuppression or previous radiation to the tumor site.
T O L K A C H J O V E T A L
23,33,34
One of 8 patients in the cohort (12.5%) was immunosuppressed at the time of diagnosis, and patients with Muir-Torre were excluded from the study.
Myriad treatment options have been used, 26 although MMS appears to offer the lowest risk of recurrence and metastasis. 26, 35 Of the 2 recurrences observed in the population, 1 was treated with excision, whereas the other had no additional treatment beyond biopsy. Of the 3 patients treated with MMS, none experienced a local recurrence.
Dermatofibrosarcoma Protuberans
The DFSP is a low-grade cutaneous soft tissue sarcoma that is locally aggressive and is associated with a high rate of recurrence. 36 It has a low metastatic potential (1%-5%) 37, 38 ; however, due to its recurrence potential, early surgical therapy is recommended. [39] [40] [41] [42] [43] The reported incidence of DFSP ranges from 0.8 to 5 per million. 44, 45 A SEER study from 1972 to 2002
reported the incidence of DFSP at 4.2 per million, 46 whereas another from 1992 to 2004 estimated an incidence of 4.5 per million. 47 A recent populationbased study from Denmark reported the overall incidence as 0.53 per 100,000 persons, 48 similar to the estimate of 0.4 per 100,000 persons. The DFSP is found in similar frequencies in men and women, although a slight male predominance has been suggested. 36, 49, 50 This was confirmed by the ageadjusted incidence of 0.3 per 100,000 in women and 0.5 per 100,000 in men. A significantly higher frequency has been suggested in blacks than whites with an incidence 6.5 per million and 3.9 per million, respectively, 46, 47, [51] [52] [53] although the incidence is increasing in among whites. 46 Unlike most tumors investigated in the study, DFSP is typically seen in a younger demographic. It is most frequently diagnosed between the ages of 30 and 50 years. 36, 44, 48 The average age of diagnosis in the population was 37.7 years. The trunk is involved in 50% of published cases, 36 with the upper extremities being the next most common site (20%-35%). In the study population, most (80%) were located on the trunk.
Early studies demonstrated a recurrence rate of 10% to 60% with excision, [54] [55] [56] [57] whereas more recent reports estimate a 4% to 7% recurrence. 48, 58 Surgical margins for DFSP have varied, but 1 study showed that 22% of tumors were removed with a 0.5-cm margin, 50% with a 1.0-cm margin, 67% with a 1.5-cm margin, and 89% with a 2.0-cm margin. 57 Today, MMS is often the preferred method for tumor clearance with an average recurrence rate around 0.6%.
57,59-61
Although 60% of patients with DFSP in the population underwent MMS, no recurrences or metastases were recorded at a median follow-up of 3.2 years.
Microcystic Adnexal Carcinoma
Microcystic adnexal carcinoma is a neoplasm with pilar and eccrine differentiation first described by Goldstein and colleagues in 1982. 62 It is locally aggressive and often extends beyond clinical margins, invading into nerves and muscle. [63] [64] [65] [66] These tumors are typically asymptomatic, although they may present with numbness, tenderness, burning, anesthesia, or paresthesia. 64, 65, 67 A 2008 literature review revealed just over 300 reported cases worldwide since 1982. 66 A SEER study from 1973 to 2004 found 223 cases, 68 an incidence of 6.5 per 10,000,000 for whites, 1.9 per 10,000,000 for blacks, and 1.6 per 10,000,000 for Asian/Pacific Islanders. The population demonstrated an incidence
of 0.7 (0.2-1.3) per 100,000 persons. Consistent with previous studies, 66 the rate of metastasis in the SEER study was very low (0.4%). 68 Similarly, the authors noted no metastases among those diagnosed with MAC in the population. An essentially equal gender distribution (51% men) was reported in a review of 105 cases in the English literature, 64 although the SEER study demonstrated a slight female predominance (57% women). 68 The results of the present study, though limited, were more in line with the SEER study findings, with a 75% female predominance. A head and neck predilection of 74% to 88% has been reported, 66, 68 and 100% of the cases were on the head and neck.
Although overall survival is excellent, 66,68 significant morbidity may be associated with MAC because of its locally invasive nature. Microcystic adnexal carcinoma has been demonstrated to offer a decreased likelihood of recurrence and metastasis, with tissuesparing and fewer procedures for tumor clearance. 63, 64, 66, 69 In the cohort, 75% of MACs were treated with MMS without recurrence.
Eccrine Carcinoma and Eccrine Porocarcinoma
Eccrine carcinoma often designates a nonspecific epithelial neoplasm with eccrine sweat gland differentiation or may include other eccrine tumors such as EPC, syringoid EC, adenoid cystic, mucinous EC, and clear cell EC. 70 Accounting for the heterogeneous appearance, nomenclature, and behavior of sweat gland carcinomas, EC represent an estimated 0.005% of all malignant epithelial neoplasms. 71, 72 A SEER study from 2001 to 2006 reported the overall US incidence of EC as 0.4 per million, with equivalent incidence among men and women. 73 A similar incidence of 0.4 per million was seen with EPC with men having a more frequent tumor burden of 0.5 compared with 0.2 per million in women. 73 The study demonstrated an incidence of 0.4 (0-0.8) and 0.2 (0-0.4) per 100,000 for EC and EPC, respectively.
Both MMS and excisions with 2-to 3-cm margins have been used demonstrating a 20% recurrence and 20% metastatic rate to regional lymph nodes (LN) for EPC. [74] [75] [76] [77] [78] When LNs are involved, the rate of distant metastasis is estimated at 12% and the mortality rate of EPC has been reported as high as 67%. 72, 74, 79, 80 No cases of EPC recurrence with MMS have been reported, while 1 EPC metastasized to LN within 2 months of MMS. 74, 81, 82 In the study, MMS was performed in 2 EC and 1 EPC, and excision done in 2 EC and 1 EPC, respectively, with no recurrences or metastases.
Leiomyosarcoma
Leiomyosarcoma is a rare smooth muscle tumor often presenting as a painful solitary nodule on the extensor surfaces of the extremities. [83] [84] [85] [86] [87] It is subdivided into dermal and subcutaneous forms. These classifications are often grouped, but evidence shows that these 2 subtypes behave very differently. 83, [86] [87] [88] Dermal LMS is thought to have a benign course with few studies showing metastatic potential. 89 Subcutaneous LMS invariably behaves more aggressively, with high recurrence, metastatic, and disease-specific mortality rates. 83, 87 In addition to subcutaneous classification, tumor size is independently associated with poor outcomes. 84, 86, 87, 90 A study of 12,114 cutaneous soft tissue sarcomas (CSTS) in 13 SEER registries, 47 classified 270 LMS (2.2% of CSTS), occurring primarily among whites (91% of LMS). The overall incidence of LMS was 0.6 per million, with the incidence for men and women being 1.1 and 0.3 per million, respectively. Two incident cases of LMS were seen in the population with an age-adjusted incidence of 0.2 per 100,000. Reports have shown that cutaneous LMS tends to occur most commonly in male patients aged 50 to 80 years. 88, 90 The aforementioned SEER study showed a 3:1 maleto-female ratio. 47 Both LMS cases in the study were men aged 58 and 77 years at the time of diagnosis.
Treatment of cutaneous LMS is typically surgical. Margin clearance status has been shown to be the most important predictor of recurrence. 83, 88 Wide local excision has demonstrated statistically lower rates of both recurrence and metastasis than surgery with narrow margins, 87 and no recurrences or metastases were seen among those treated with MMS. The patients underwent local excision without recurrence or metastasis.
Conclusion
To the authors' knowledge, this is the most inclusive report of population incidence of rare adnexal cutaneous malignancies and the first population-based report of the incidence of AFX, SC, MAC, EC, EPC, and LMS. The incidences of these tumors range from 0.2 per 100,000 for LMS and EPC to 1.8 per 100,000 for AFX. These data add to the understanding of the epidemiology of these rare tumors, the characteristics of the affected patients, and their outcomes by treatment modality. Additional studies in a larger population with a wider racial spectrum would contribute to better understanding of the true incidence and outcomes of these malignancies.
